Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
22 stopped studies mapped to T Acute Lymphoblastic Leukemia and descendants · 86% state a reason
Over the 22 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06738368 | Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or… | Phase 2 | suspended | Dec 17, 2024 | University of Washington | Safety Review | Safety / toxicity |
| NCT05277753 | NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL | Phase 1 | terminated | Mar 14, 2022 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT07585734 | Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute… | Phase 1 / Phase 2 | withdrawn | May 14, 2026 | Institute of Hematology & Blood Diseases Hospital, China | drug-associated adverse reactions | Safety / toxicity |
| NCT03808610 | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or… | Phase 1 / Phase 2 | terminated | Jan 17, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05909527 | A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute… | Phase 1 / Phase 2 | withdrawn | Jun 18, 2023 | Guangzhou Bio-gene Technology Co., Ltd | Due to corporate strategic adjustment. | Sponsor / business decision |
| NCT05032183 | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed… | Phase 1 / Phase 2 | terminated | Sep 2, 2021 | M.D. Anderson Cancer Center | The study was terminated early due to slow enrollment. | Enrollment / accrual |
| NCT05038644 | XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic… | Phase 1 | terminated | Sep 9, 2021 | Ehab L Atallah | Drug expired May 31, 2024. | Other (stated, no rule matched) |
| NCT05032599 | Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute… | Phase 1 | terminated | Sep 2, 2021 | Beijing Boren Hospital | ethic commitee decision | Other (stated, no rule matched) |
| NCT06210750 | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute… | Phase 2 | withdrawn | Jan 18, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
| NCT04828174 | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies | Phase 1 | suspended | Apr 1, 2021 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | The trial was suspended due to the inability to enroll qualified participants | Enrollment / accrual |
| NCT02763384 | BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/… | Phase 2 | terminated | May 5, 2016 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT05320380 | A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment… | Phase 1 / Phase 2 | withdrawn | Apr 11, 2022 | Children's Oncology Group | Withdrawn per CS0150757 | Other (stated, no rule matched) |
| NCT05519527 | STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL… | Phase 1 | withdrawn | Aug 29, 2022 | M.D. Anderson Cancer Center | 0 patient accrual | Enrollment / accrual |
| NCT04860817 | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and… | Early Phase 1 | withdrawn | Apr 27, 2021 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | No proper participant is found. | Other (stated, no rule matched) |
| NCT03519984 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With… | Phase 1 | terminated | May 9, 2018 | University of Southern California | Study drug supply issue | Drug supply |
| NCT01483690 | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | Phase 1 / Phase 2 | terminated | Dec 1, 2011 | Therapeutic Advances in Childhood Leukemia Consortium | Toxicity | Safety / toxicity |
| NCT00981799 | Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL | Phase 1 / Phase 2 | terminated | Sep 22, 2009 | Therapeutic Advances in Childhood Leukemia Consortium | Slow accrual rate | Enrollment / accrual |
| NCT02767934 | Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic… | Phase 2 | terminated | May 11, 2016 | University of Washington | Terminated due to lack of efficacy | Efficacy / futility |
| NCT02538926 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin… | Phase 2 | withdrawn | Sep 2, 2015 | University of Washington | Drugs unavailable | Other (stated, no rule matched) |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or… | Phase 1 | terminated | Mar 17, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 9 hours agoSource updated Sep 29, 2026source: clinicaltrials